

DAFTAR PUSTAKA

- Ahren, B., Foley, J.E., Bosi, E. (2011). Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. *Diabetes Obes Metab*, 13, 193–203.
- Allredge, B. K., Corelli, R. L., Ernst, M. E., Guglielmo, B. J., Jacobson, P. A., Kradjan, W. A., Williams, B. R. (2013). *Koda-Kimble & Young's Applied Therapeutics The Clinical Use of Drugs Tenth Edition*. Lippincott Williams & Wilkins. Philadelphia. United States of America.
- American Diabetes Association (ADA). (2016). *Standards of Medical Care in Diabetes-2016*. Vol. 39. ADA. USA.
- Aoki, K., Kamiyama, H., Yoshimura, K., Shibuya, M., Masuda, K., Terauchi, Y. (2012). Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin. *Acta Diabetol*, 49, 225–30.
- Arisman, M. B. (2010). *Buku Ajar Ilmu Gizi Obesitas, Diabetes Mellitus, dan Dislipidemia: Konsep, Teori, dan Penanganan Aplikatif*. EGC. Jakarta.
- Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI (RISKESDAS). (2018). Hasil Utama Riskesdas 2018. Jakarta. RISKESDAS. Retrieved from: <https://www.kemkes.go.id/resources/download/informasi/hasil-riskesdas-2018.pdf>
- Barnett A., Allsworth, J., Jameson, K., *et al.* (2007). A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies. *Curr Med Res Opin*, 23, 1493–1507.
- Bilous R. dan Richard D. (2014). *Buku Pegangan Diabetes*. Edisi ke 4. Bumi Medika. Jakarta.
- Cefalu, W. T., *et al.* (2017). *Standards of Medical Care in Diabetes-2017*. Vol. 40, Supplement 1. ADA. USA.
- Decroli, E. (2019). *Diabetes Melitus Tipe 2*. Edisi Pertama. Pusat Penerbitan Bagian Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Andalas. Padang.
- Departemen Kesehatan RI (DEPKES RI). (2005). *Pharmaceutical Care untuk Penyakit Diabetes Melitus*. DEPKES. Jakarta.

- Dipiro, Cecily V., Barbara G. Wells, Joseph T DiPiro, and Terry L. Schwinghammer. (2015). *Pharmacotherapy Handbook Ninth Edition*. McGraw-Hill Education. United States.
- Ekoe J. M., Brazeau A. S., Mircescu H., Desjardins K., Leroux C., Strychar I., *et al.* (2013). Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes. *Diabetes Res Clin Pract*, 99, 19–23.
- Fatimah, R. N. (2015). Diabetes Melitus Tipe 2. *J Majority*, 4(5), 93–101.
- Gumantara, M. P. B., Oktarlina, R. Z. (2017). Perbandingan Monoterapi dan Kombinasi Terapi Sulfonilurea-Metformin terhadap Pasien Diabetes Melitus Tipe 2. *J Majority*, 6(1), 55–59.
- Haak, T., Meinicke, T., Jones, R., Weber, S., Eynatten, M. v., & Woerle, H. -J. (2012). Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. *Diabetes Obesity and Metabolism*, 14(6), 565–574. <https://doi.org/10.1111/j.1463-1326.2012.01590.x>
- Hanum, N. N. (2013). Hubungan Kadar Glukosa Darah Puasa dengan Profil Lipid pada Pasien Diabetes Melitus Tipe 2 di Rumah Sakit Umum Daerah Kota Cilegon Periode Januari-April 2013. *Skripsi*. Program Studi Pendidikan Dokter Fakultas Kedokteran dan Ilmu Kesehatan Universitas Islam Negeri Syarif Hidayatullah. Jakarta.
- Hartini, S. (2016). Hubungan HbA1c terhadap Kadar Glukosa Darah pada Penderita Diabetes Mellitus di RSUD Abdul Wahab Syahrani Samarinda Tahun 2016. *Jurnal Husada Mahakam*, 4(3), 171-180. <https://pbperkeni.or.id/wp-content/uploads/2019/01/4.-Konsensus-Pengelolaan-dan-Pencegahan-Diabetes-melitus-tipe-2-di-Indonesia-PERKENI-2015.pdf>
- International Diabetes Federation (IDF). (2019). *IDF Diabetes Atlas Ninth Edition 2019*. Retrieved from: <https://www.diabetesatlas.org/en/resources/>
- Iwamoto, Y., Tajima, N., Kadowaki T., *et al.* (2010). Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. *Diabetes Obes Metab*, 12, 613–622.
- Kaku K. (2010). Pathophysiology of Type 2 Diabetes and Its Treatment Policy. *Japan Medical Association Journal*, 53(1), 41–46.
- Kaku, K., Itayasu, T., Hiroi, S., Hirayama, M., & Seino, Y. (2011). Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. *Diabetes, Obesity and Metabolism*, 13(11),

1028–1035. <https://doi.org/10.1111/j.1463-1326.2011.01460.x>

- Karasik, A., Aschner, P., Katzeff, H., *et al.* (2008). Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. *Curr Med Res Opin*, 24, 489–496.
- Kumar, Vinay, Ramzi S. Cotran, Stanley L. Robbins. (2007). *Buku Ajar Patologi (Edisi 7)*. Terjemah Oleh: Awal Prasetyo, Brahm U. Pundit, Toni Priliyono. EGC. Jakarta, Indonesia.
- Manzilati, A. (2017). *Metodologi Penelitian Kualitatif: Paradigma, Metode, dan Aplikasi*. UB Press. Malang.
- Masuda, K., Aoki, K., Terauchi, Y. (2011). Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance, impaired fasting glucose or impaired glucose tolerance. *Diabet Invest*, 2, 435–40.
- National Institute for Diabetes and Digestive and Kidney Disease (NIDDK). (2014). *Cause of Diabetes*. NIH Publication.
- Ndraha, S. (2014). Diabetes Melitus Tipe 2 dan Tatalaksana Terkini. *Medicinus*, 27(2), 9–16.
- Notoatmodjo, S. (2010). *Metodologi Penelitian Kesehatan*. Rineka Cipta. Jakarta.
- Perkumpulan Endokrinologi Indonesia (PERKENI). (2011). Konsensus Pengelolaan dan Pencegahan DM Tipe 2 di Indonesia. PERKENI. Jakarta. Retrieved from: https://kupdf.net/download/konsensus-dm-perkeni-2011_5bf22039e2b6f58e6abd00db_pdf
- Perkumpulan Endokrinologi Indonesia (PERKENI). (2015). Pengelolaan dan Pencegahan DM Tipe 2 di Indonesia. PERKENI. Jakarta. Retrieved from:
- Perkumpulan Endokrinologi Indonesia (PERKENI). (2019). Pedoman Pemantauan Gula Darah Mandiri. PERKENI. Jakarta. Retrieved from: <https://pbperkeni.or.id/pedoman-pengelolaan-glukosa-darah-mandiri-2019/>
- Prabawati, R. K. (2012). Mekanisme Seluler dan Molekuler Resistensi Insulin. Fakultas Kedokteran Universitas Brawijaya. Malang.
- Rachmawati, N. (2015). Gambaran Kontrol dan Kadar Gula Darah pada Pasien Diabetes Mellitus di Poliklinik Penyakit dalam RSJ. Prof. Dr. Soerojo Magelang. *Skripsi*. Program Studi Keperawatan Fakultas Kedokteran Universitas Diponegoro (UNDIP). Semarang.
- Reasner, C., Olansky, L., Seck, T. L., Williams-Herman, D. E., Chen, M., Terranella, L., Johnson-Levonas, A. O., Kaufman, K. D., & Goldstein, B. J.

- (2011). The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. *Diabetes, Obesity and Metabolism*, 13(7), 644–652. <https://doi.org/10.1111/j.1463-1326.2011.01390.x>
- Republik Indonesia. (2009). Undang-Undang RI Nomor 44 Tahun 2009 tentang Rumah Sakit.
- Republik Indonesia. (2016). *Peraturan Menteri Kesehatan Republik Indonesia Nomor 72 Tahun 2016 tentang Standar Pelayanan Kefarmasian di Rumah Sakit*. Jakarta.
- Rudi, A. dan Kwureh, H. N. (2017). Faktor Risiko yang Mempengaruhi Kadar Gula Darah Puasa pada Pengguna Layanan Laboratorium. *Wawasan Kesehatan*, 3(2), 33–39.
- Safitri, W. A. (2017). Efektivitas Penggunaan Obat Antidiabetik Oral Kombinasi pada Pasien Diabetes Melitus Tipe 2 di Instalasi Rawat Jalan RSUD Kajian Kabupaten Pekalongan Periode Januari-Desember 2017. Retrieved from: <https://e-skripsi.stikesmuh-pkj.ac.id/detail/skripsi/1993>
- Schweizer, A., Dejager, S., Foley, JE., Shao, Q., Kothny, W. (2011). Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥ 75 years: a pooled analysis from a data base of clinical trials. *Diabetes Obes Metab*, 13, 55–64.
- Seino, Y., Fujita, T., Hiroi, S., Hirayama, M., & Kaku, K. (2011). Alogliptin plus voglibose in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. *Current Medical Research and Opinion*, 27(SUPPL. 3), 21–29. <https://doi.org/10.1185/03007995.2011.614936>
- Seino, Y., Miyata, Y., Hiroi, S., Hirayama, M., & Kaku, K. (2012). Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. *Diabetes, Obesity and Metabolism*, 14(10), 927–936. <https://doi.org/10.1111/j.1463-1326.2012.01620.x>
- Siswandono dan Soekardjo B. (2008). *Kimia Medisinal Edisi 2*. Erlangga. Surabaya.
- Smeltzer, S. C. dan Bare, B. G.. 2008. *Buku Ajar Keperawatan Medikal Bedah Brunner dan Suddarth*. EGC. Jakarta.
- Sofianingrum, N. D. (2019). Efektivitas Antidiabetik Oral Baik Kombinasi Maupun Tunggal pada Pasien Diabetes Mellitus Tipe II di RSUD Kota Madiun. *Karya Tulis Ilmiah*. Program Studi D-III Farmasi Stikes Bhakti Husada Mulia Madiun. Madiun.

- Søfteland, E., Meier, J. J., Vangen, B., Toorawa, R., Maldonado-Lutomirsky, M., & Broedl, U. C. (2017). Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: A 24-week randomized, double-blind, parallel-group trial. *Diabetes Care*, 40(2), 201–209. <https://doi.org/10.2337/dc16-1347>
- Strojek, K., Yoon, K. H., Hrubá, V., Sugg, J., Langkilde, A. M., & Parikh, S. (2014). Dapagliflozin Added to Glimepiride in Patients with Type 2 Diabetes Mellitus Sustains Glycemic Control and Weight Loss Over 48 Weeks: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial. *Diabetes Therapy*, 5(1), 267–283. <https://doi.org/10.1007/s13300-014-0072-0>
- Sugiyono (2012). *Metode Penelitian Kuantitatif, Kualitatif dan R & D*. Alfabeta. Bandung.
- Tajima, N., Kadowaki, T., Okamoto, T., Sato, A., Okuyama, K., Minamide, T., & Arjona Ferreira, J. C. (2013). Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes. *Journal of Diabetes Investigation*, 4(6), 595–604. <https://doi.org/10.1111/jdi.12116>
- Umpierrez, G. E. (2014). *Therapy for Diabetes Mellitus and Related Disorders 6th Edition*. American Diabetes Association. Alexandria.
- Wang, Q., Su, Y., & Lv, L. (2015). A randomized controlled clinical trial of combination therapy for type 2 diabetes by vildagliptin, metformin, and α -glucosidase inhibitor. *International Journal of Diabetes in Developing Countries*, 36(4), 420–425. <https://doi.org/10.1007/s13410-015-0388-y>
- Wang, W., Ning, G., Ma, J., Liu, X., Zheng, S., Wu, F., Xu, L., O'Neill, E. A., Fujita, K. P., Engel, S. S., Kaufman, K. D., & Shankar, R. R. (2017). A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone. *Current Medical Research and Opinion*, 33(4), 693–699. <https://doi.org/10.1080/03007995.2016.1277200>
- World Health Organization (WHO). (2016). *Global Report on Diabetes*. Retrieved from: <https://www.who.int/diabetes/global-report/en/>
- World Health Organization. (2019). *Classification of Diabetes Mellitus 2019*. Retrieved from: <https://www.who.int/publications-detail/classification-of-diabetes-mellitus>
- Zahtamal, Chandra, F., Suyanto, dan Restuastuti, T. (2007). Faktor-Faktor Risiko Pasien Diabetes Melitus. *Berita Kedokteran Masyarakat*, 23(3), 142–147.
- Zed, M. (2014). *Metode Penelitian Kepustakaan*. Yayasan Pustaka Obor Indonesia. Jakarta.